Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02768662 · ClinicalTrials.gov registry record · Phase 3
A 6-Month Extension Study of OTO-104 in Meniere's Disease
A Phase 3 study, sponsored by Otonomy.
- Terminated
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
NCT02768662 is a Phase 3 study that was terminated before completion, run by Otonomy. The registered enrollment target is 142 participants.
The verdict
NCT02768662, a Phase 3 study, was terminated before completion, sponsored by Otonomy.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
Study Summary
This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections. Subjects must have completed either Otonomy study 104-201403 (1-Year, Phase 2, Safety Study of OTO-104) or 104-201508 (Phase 3 Study of OTO-104) in order to be eligible for this open-label extension study.
Interventions
- DRUG OTO-104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02768662
The ClinicalTrials.gov registry entry for NCT02768662 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otonomy, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OTO-104 is the first listed.
NCT02768662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02768662 about?
NCT02768662 is a clinical study titled "A 6-Month Extension Study of OTO-104 in Meniere's Disease". This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections. Subjects must have completed either Otonomy study 104-201403 (1-Year, Phase 2, Safety Study of OTO-104) or 104-201508 (Phase 3 Study of OTO-104) in order to be eligi...
What is the current status of trial NCT02768662?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2016-08. Estimated completion is 2017-09.
What interventions are being tested in trial NCT02768662?
The interventions under investigation include: OTO-104 (DRUG).
Who is sponsoring clinical trial NCT02768662?
This trial is sponsored by Otonomy, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.